

Eleven-Year Trends in Antimicrobial Resistance and Isolation Rates per 1000 Patient-Days of Key Gram-Positive and Gram-Negative Bacteria in a Tertiary Care Hospital in Türkiye (2014–2024)

SUPPLEMENTARY APPENDIX 1

Balkaya Demirtaş R, Metan G, Telli Dizman G, Hazirolan G, Akova M, Uzun Ö. Eleven-year trends in antimicrobial resistance and isolation rates per 1000 patient-days of key Gram-positive and Gram-negative bacteria in a tertiary care hospital in Türkiye (2014–2024). *Infect Dis Clin Microbiol.* 2026;8(5):446–60.

The authors provide the tables and figures in the supplementary appendix to give readers detailed information about the study.

Section S1. Antibacterial Resistance Trends

Figure S1. Joinpoint regression analysis of the high-dose gentamicin resistance rate in *E. faecalis* among bloodstream isolates, 2015–2024.





Figure S2. Joinpoint regression analysis of the high-dose gentamicin resistance rate in *E. faecalis* among non-bloodstream isolates, 2015–2024.






Figure S3. Joinpoint regression analysis of the ampicillin resistance rate in *E. faecium* among bloodstream isolates, 2014–2024.




Figure S4. Joinpoint regression analysis of the ampicillin resistance rate in *E. faecium* among non-bloodstream isolates, 2014–2024.




Figure S5. Joinpoint regression analysis of the high-dose gentamicin resistance rate in *E. faecium* among bloodstream isolates, 2014–2024.




Figure S6. Joinpoint regression analysis of the high-dose gentamicin resistance rate in *E. faecium* among non-bloodstream isolates, 2014–2024.




Figure S7. Joinpoint regression analysis of the vancomycin resistance rate in *E. faecium* among bloodstream isolates, 2014–2024.




Figure S8. Joinpoint regression analysis of the vancomycin resistance rate in *E. faecium* among non-bloodstream isolates, 2014–2024.

Staphylococcus aureus




Figure S9. Joinpoint regression analysis of the cefoxitin resistance rate in *S. aureus* among bloodstream isolates, 2014–2024.




Figure S10. Joinpoint regression analysis of the cefoxitin resistance rate in *S. aureus* among non-bloodstream isolates, 2014–2024.

Escherichia coli




Figure S11. Joinpoint regression analysis of the third-generation cephalosporin resistance rate in *E. coli* among bloodstream isolates, 2014–2024.




Figure S12. Joinpoint regression analysis of the third-generation cephalosporin resistance rate in *E. coli* among non-bloodstream isolates, 2014–2024.




Figure S13. Joinpoint regression analysis of the piperacillin-tazobactam resistance rate in *E. coli* among bloodstream isolates, 2014–2024.




Figure S14. Joinpoint regression analysis of the piperacillin-tazobactam resistance rate in *E. coli* among non-bloodstream isolates, 2014–2024.




Figure S15. Joinpoint regression analysis of the meropenem resistance rate in *E. coli* among bloodstream isolates, 2014–2024.




Figure S16. Joinpoint regression analysis of the meropenem resistance rate in *E. coli* among non-bloodstream isolates, 2014–2024.




Figure S17. Joinpoint regression analysis of the amikacin resistance rate in *E. coli* among bloodstream isolates, 2014–2024.




Figure S18. Joinpoint regression analysis of the amikacin resistance rate in *E. coli* among non-bloodstream isolates, 2014–2024.




Figure S19. Joinpoint regression analysis of the ciprofloxacin resistance rate in *E. coli* among bloodstream isolates, 2014–2024.




Figure S20. Joinpoint regression analysis of the ciprofloxacin resistance rate in *E. coli* among non-bloodstream isolates, 2014–2024.

Klebsiella pneumoniae




Figure S21. Joinpoint regression analysis of the third-generation cephalosporin resistance rate in *K. pneumoniae* among bloodstream isolates, 2014–2024.




Figure S22. Joinpoint regression analysis of the third-generation cephalosporin resistance rate in *K. pneumoniae* among non-bloodstream isolates, 2014–2024.




Figure S23. Joinpoint regression analysis of the meropenem resistance rate in *K. pneumoniae* among bloodstream isolates, 2014–2024.




Figure S24. Joinpoint regression analysis of the meropenem resistance rate in *K. pneumoniae* among non-bloodstream isolates, 2014–2024.




Figure S25. Joinpoint regression analysis of the amikacin resistance rate in *K. pneumoniae* among bloodstream isolates, 2014–2024.




Figure S26. Joinpoint regression analysis of the amikacin resistance rate in *K. pneumoniae* among non-bloodstream isolates, 2014–2024.




Figure S27. Joinpoint regression analysis of the colistin resistance rate in *K. pneumoniae* among bloodstream isolates, 2014–2024.




Figure S28. Joinpoint regression analysis of the colistin resistance rate in *K. pneumoniae* among non-bloodstream isolates, 2014–2024.




Figure S29. Joinpoint regression analysis of the ceftazidime-avibactam resistance rate in *K. pneumoniae* among bloodstream isolates, 2020–2024.




Figure S30. Joinpoint regression analysis of the ceftazidime-avibactam resistance rate in *K. pneumoniae* among non-bloodstream isolates, 2020–2024.

Pseudomonas aeruginosa




Figure S31. Joinpoint regression analysis of the ceftazidime resistance rate in *P. aeruginosa* among bloodstream isolates, 2014–2024.




Figure S32. Joinpoint regression analysis of the ceftazidime resistance rate in *P. aeruginosa* among non-bloodstream isolates, 2014–2024.




Figure S33. Joinpoint regression analysis of the piperacillin-tazobactam resistance rate in *P. aeruginosa* among bloodstream isolates, 2014–2024.




Figure S34. Joinpoint regression analysis of the piperacillin-tazobactam resistance rate in *P. aeruginosa* among non-bloodstream isolates, 2014–2024.




Figure S35. Joinpoint regression analysis of the meropenem resistance rate in *P. aeruginosa* among bloodstream isolates, 2014–2024.




Figure S36. Joinpoint regression analysis of the meropenem resistance rate in *P. aeruginosa* among non-bloodstream isolates, 2014–2024.




Figure S37. Joinpoint regression analysis of the amikacin resistance rate of *P. aeruginosa* in bloodstream isolates, 2014–2024.




Figure S38. Joinpoint regression analysis of the amikacin resistance rate in *P. aeruginosa* among non-bloodstream isolates, 2014–2024.

Acinetobacter baumannii




Figure S39. Joinpoint regression analysis of the meropenem resistance rate in *A. baumannii* among bloodstream isolates, 2014–2024.




Figure S40. Joinpoint regression analysis of the meropenem resistance rate in *A. baumannii* among non-bloodstream isolates, 2014–2024.




Figure S41. Joinpoint regression analysis of the colistin resistance rate in *A. baumannii* among bloodstream isolates, 2014–2024.




Figure S42. Joinpoint regression analysis of the colistin resistance rate in *A. baumannii* among non-bloodstream isolates, 2014–2024.